3 Synthetic Biology Stocks That Can Help You Grow in 2014 (and Beyond)

Large-scale genome editing can create entirely new organisms, but it can also create a number of growth opportunities for your portfolio. Here's how Agilent Technologies, Intrexon, and Solazyme can keep your portfolio chugging along in 2014.

Jan 22, 2014 at 6:30PM

Synthetic biology is relatively new, but the field holds near-limitless potential to shape every aspect of our daily lives. While it's easy to think the industry will only have a major impact in industrial applications, at companies such as Amyris and Solazyme (NASDAQ:SZYM), there are numerous unrelated industries waiting to be forever changed by large-scale genetic tinkering. How can Agilent Technologies (NYSE:A), Intrexon (NYSE:XON), and Solazyme power your portfolio higher in 2014 and beyond?

Agilent Technologies

^SPXTR Chart

^SPXTR data by YCharts.

You may associate Agilent with its core business of providing bioanalytical measurement solutions, but the $20 billion company refuses to miss out on the growth opportunity presented by synthetic biology. After seeing the exploding need for synthetic genes and developing an industry-leading platform for creating short, single-stranded DNA (oligonucleotides), the company made a $21 million investment in DNA synthesis start-up Gen9 that combined each company's sequencing library in return for an equity stake and a position on the board. Prior to that in early 2011, Agilent helped to launch the UC Berkeley Synthetic Biology Institute to spur development in the field.  

I think the investment spree is a brilliant idea. Agilent is positioning itself to greatly increase the number of potential customers that will need its analytical services by fueling growth of the nascent synthetic biology industry. While nothing is guaranteed, the investments could help ease investor concerns of slowing revenue growth and profits that have occurred in the last several fiscal years. I wouldn't begin to think that management is done cutting checks to tap into the market, either.

Intrexon

^SPXTR Chart

^SPXTR data by YCharts.

A few months ago, I voiced three of my concerns with synthetic biology leader Intrexon: The company had partnerships with mostly unproven companies; Wall Street was setting impossible expectations, and shares looked a little frothy given the long time horizon for revenue generation. Since then, collaborations with Johnson & Johnson and Sun Pharma have partially eased my worries about attracting well-funded customers, although Wall Street and a soaring valuation remain red flags. While I'll admit that my views on company valuation are in the process of evolving, I'm still scared of Wall Street's potential to screw things up.

Assuming unrealistic revenue targets don't get in the way, Intrexon is a spectacular long-term growth opportunity that could wield a diverse portfolio of multimillion- or multibillion-dollar products spanning health care, chemical manufacturing, aquaculture, agriculture, and environmental remediation within the next decade. I can't promise shares won't deflate after a 55% climb to begin 2014, but racking up more development collaborations this year and the approval of the first genetically engineered Atlantic salmon would give investors plenty to cheer about.

Solazyme

^SPXTR Chart

^SPXTR data by YCharts.

While I've tried hard to remain objective and level-headed about the tremendous growth opportunity in the making at Solazyme in the last two years, it is difficult to keep my optimism from boiling over as 2014 gets under way. The well-capitalized industrial biotech company will soon begin operations at its first two commercial scale facilities on its way to 120,000 metric tons of annual renewable oil production capacity by mid-2015. In other words, Solazyme will go from a little more than $50 million in annual revenue in 2013 to several hundred million dollars in annual revenue by 2015 and beyond.

Investors aren't out of the woods yet, especially considering the wide range of potential obstacles facing ramp-up, but there likely won't be another opportunity to buy Solazyme under $1 billion after 2014 is in the books. The company is forging ahead with its disruptive platform for creating renewable oils with identical or superior performance compared to those created by other processes and continues to attract partners in various industries. That will help distribute, but not eliminate, development risks while insulating the company's product portfolio from volatility.

Foolish bottom line
The way I see it, there is an obvious growth opportunity brewing in the synthetic biology industry for long-term investors. There will inevitably be hurdles for each company above as they pioneer new technologies with disruptive potential, but the long-term rewards far outweigh the risks of development. If you can stomach the occasional big drop -- and use it as a buying opportunity -- then you, too, can make synthetic biology an integral part of your investment portfolio and retirement plan.

Until synthetic biology arrives in health care...
Intrexon will take some time to disrupt the health-care industry in an impactful way for investors, so you may want to look elsewhere for more immediate opportunities. Let's face it, the best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS pagehis previous writing for The Motley Fool, or his work for the SynBioBeta Blog to keep up with developments in the synthetic biology industry.

The Motley Fool owns shares of Solazyme. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers